LTQ Orbitrap XL FT-LC/MSn mass spectrometer

LTQ Orbitrap XL FT-LC/MSn 质谱仪

• 批准号: 7792882
• 负责人: Joseph DiDonato
• 金额: $ 50万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-25 至 2011-03-24
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7792882
• 关键词: Affect; Amino Acid Sequence; Area; Biological Markers; Clinic; Clinical; Commit; Custom; Development; Disease; Disease Pathway; Distant; Early Diagnosis; Evaluation; Funding; Grant; Health; Human; Human Resources; Institution; Investigation; Laboratories; Maintenance; Mass Spectrum Analysis; Ohio; Outcome; Peptide Sequence Determination; Productivity; Program Research Project Grants; Research; Research Personnel; Research Project Grants; Resolution; Resources; Sampling; Schedule; Sensitivity and Specificity; Services; Technology; Time; Travel; Universities; analytical tool; base; instrument; instrumentation; mass spectrometer; member; metabolomics; novel; operation; prognostic; programs; public health relevance; translational study

DESCRIPTION (provided by applicant): The purpose of this proposal is to seek funds for the purchase of an LTQ OrbiTrap XL Mass Spectrometer. This instrument will expand and upgrade mass spectrometry capabilities within the Northeastern Ohio region, advancing research programs within the Cleveland Clinic (CC) and its partner institution, Case Western Reserve University (CWRU) other Cleveland CTSA member institutions and Cleveland State University (CSU). Major Users all have NIH-funded research grants, including recent multiple Program Project Grants and SCCOR programs, all which have Projects that rely heavily on using mass spectrometry to ask, investigate and answer key questions concerning major diseases that affect human health. Due to the absence of available high resolution instrumentation in the region for metabolomics-based studies the Major Users in this proposal now have to schedule time many months in advance to obtain access to this technology and/or travel to distant (>550 miles) institutions. As detailed in the application, supported projects primarily include biomarker discovery and clinical/translational studies nearly all of which also utilize the NCRR-funded Cleveland CTSA. The requested mass spectrometer provides the high resolution capabilities that allow unbiased metabolomics studies to be performed. Availability of this instrument will assure area investigators access high resolution mass spectrometry, while enhancing the versatility, sensitivity and specificity required for their projects. This analytical activity will be conducted within our existing Mass Spectrometry Core II, which provides support to investigators at CC, CWRU, CSU and neighboring institutions by performing structural elucidation studies, biomarker quantification, protein sequencing/identification, and related services. Mass spectrometry is increasingly being used as an analytical tool by CC and partner institution investigators, with demand greatly outpacing availability, resulting in significant delays in access, and hampered productivity. The acquisition of the requested mass spectrometer is essential to provide an unmet need for instrumentation to perform metabolomics-based investigations. Cleveland Clinic has committed substantial resources to the development of mass spectrometry in the region, including custom renovation of laboratory space for Mass Spectrometry Core II, personnel to oversee its operation, and a fiscal plan to insure its operation and maintenance for the long-term. PUBLIC HEALTH RELEVANCE: The major users group, of this shared mass spectrometry instrumentation grant, direct multiple very large clinical sample-based NIH-funded grants. The Major Users have projects that require the use of the requested instrumentation to ask, investigate and answer key questions concerning major diseases that affect human health. These projects primarily include disease biomarker discovery and clinical/translational studies that will allow and facilitate discovery of novel disease pathways and metabolites, early detection of disease states and/or provide prognostic evaluation of the disease state based upon clinical sample outcomes.

描述（由申请人提供）：本提案的目的是寻求购买LTQ OrbiTrap XL质谱仪的资金。该仪器将扩展和升级俄亥俄州东北部地区的质谱分析能力，推进克利夫兰诊所（CC）及其合作机构、凯斯西储大学（CWRU）、克利夫兰CTSA其他成员机构和克利夫兰州立大学（CSU）的研究计划。主要用户都有NIH资助的研究经费，包括最近的多个计划项目赠款和SCCOR计划，所有这些项目都严重依赖于使用质谱来询问，调查和回答有关影响人类健康的重大疾病的关键问题。由于该地区缺乏可用于代谢组学研究的高分辨率仪器，本提案中的主要用户现在必须提前数月安排时间才能获得该技术和/或前往遥远的（>550英里）机构。如申请中所述，支持的项目主要包括生物标志物发现和临床/转化研究，几乎所有这些研究都利用了NCRR资助的克利夫兰CTSA。所要求的质谱仪具有高分辨率功能，可进行无偏倚的代谢组学研究。该仪器的可用性将确保区域调查人员获得高分辨率质谱，同时提高其项目所需的多功能性，灵敏度和特异性。这项分析活动将在我们现有的质谱核心II中进行，该核心II通过进行结构解析研究、生物标志物定量、蛋白质测序/鉴定和相关服务为CC、CWRU、CSU和邻近机构的研究人员提供支持。质谱越来越多地被CC和合作机构研究人员用作分析工具，需求大大超过可用性，导致访问严重延迟，并阻碍了生产力。获得所要求的质谱仪对于提供未满足的仪器需求以进行基于代谢组学的研究至关重要。克利夫兰医学中心已投入大量资源用于该地区的质谱发展，包括为质谱核心II定制翻新实验室空间，监督其运行的人员，以及确保其长期运行和维护的财政计划。 公共卫生相关性：这个共享的质谱仪器拨款的主要用户组，直接多个非常大的临床样本为基础的NIH资助的赠款。主要用户的项目需要使用所要求的仪器来询问、调查和回答有关影响人类健康的主要疾病的关键问题。这些项目主要包括疾病生物标志物发现和临床/转化研究，这些研究将允许和促进发现新的疾病途径和代谢物，早期检测疾病状态和/或根据临床样本结果提供疾病状态的预后评估。